Enrollment for a new cystic fibrosis (CF) treatment has begun in Israel for a multi-center, open label, Phase II clinical trial for the experimental drug NOxCureCF. NOxCureCF is a formulation of inhaled nitric oxide (NO) developed by Advanced Inhalation Therapies (AIT Ltd.). According to David Greenberg, M.D., AIT’s Chief Medical Officer and a professor of pediatrics and infectious diseases at Soroka Medical Center in Beersheva: “This study, in combination with the continuation of our Phase II trial of the use of NO for treatment of infants with RSV/bronchiolitis, will allow us to substantiate and enhance the use of inhaled NO in the treatment of respiratory disease and distress.” NO is a naturally produced gas that acts as an anti-infection agent that makes it very effective for treatment of a number of diseases.
The goal of this trial is to assess the improvement in lung function after NOxCureCF therapy is administered to cystic fibrosis patients 10 years old and older. The trial will allow for testing of safety and tolerability of the dosage and delivery system. The delivery system was designed by AIT Ltd.
Find out more about cystic fibrosis.
Prof. Asher Tal, head of the Pediatrics Department at Soroka University Medical Center, notes, “The NOxCureCF treatment may serve as a major improvement in the quality of life for CF patients, and may significantly contribute to their life expectancy”. The trial will take place at Soroka’s CF clinic which is led by Dr. Mica Aviram.
According to Prof Yossef Av Gay, AIT’s CSO and a professor of microbiology at the University of British Columbia, Canada, “The ongoing studies, an outgrowth of the strategic alliance between Clalit Health Services and AIT, will strengthen the research and development in the critically important area of treatment of acute and chronic respiratory illness treatment with NO solutions.”
Unfortunately, the clinical trial for NOxCureCF is not available to cystic fibrosis patients in the United States. However, there are other experimental dugs currently being tested in nationwide trials that are currently recruiting.